Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

STOCKHOLDERS' EQUITY (DEFICIT):

Schedule of share-based compensation, stock options, activity

	Shares Underlying Options			Weighted Average Exercise Price		Weighted average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2017		-		$	-		-		-
Acquired in Reverse Merger		133,711			36.42		4.13		-
Granted		68,347			12.24		9.51		-
Forfeited		(45,178	)		11.64		-		-
Outstanding at September 30, 2018		156,880		$	33.00		4.91		-

Schedule of share-based compensation

	Three Months ended September 30,				Nine Months ended September 30,
	2018		2017		2018		2017
Research and development		2,127		-		8,837		-
General and administrative		785,609		288,308		1,979,551		709,000
Total	$	787,736	$	288,308	$	1,988,388	$	709,000

Schedule of share-based payment award, stock options, valuation assumptions

Fair value of common stock	$10.92 - $13.26
Expected volatility	118.10% - 143.50%
Dividend yield	$0
Risk-free interest	2.85% - 3.00%
Expected life (years)	5.125 - 5.33

Schedule of common stock warrant activity

	Number of  Warrants			Weighted Average Exercise Price
Outstanding, December 31, 2017		146,358		$	59.04
Acquired, H-1 warrants		50,744			29.04
Acquired, H-3 warrants		14,001			33.12
Granted, H-4 warrants		447,383			3.60
Granted, I warrants		73,178			13.80
Granted, J warrants		260,116			6.00
Exercised, H-4 warrants		(260,116	)		3.60
Retired, Merger warrants		(146,357	)		59.04
Outstanding, September 30, 2018		585,307		$	12.72